Investors purchased NASDAQ: IVVD shares between November 29 and December 14, 2021, should contact the Shareholders Foundation in connection with the Lawsuit against Invivyd, Inc.
03/01/2023 - 04:15 PM
SAN DIEGO, CA / ACCESSWIRE / March 1, 2023 / The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in of Invivyd, Inc. (NASDAQ:IVVD) shares over alleged securities laws violations by Invivyd, Inc. f.k.a. Adagio Therapeutics, Inc.
Investors, who purchased shares of Invivyd, Inc. (NASDAQ:IVVD) between November 29, 2021, and December 14, 2021, have certain options and there are short and strict deadlines running. Those NASDAQ: IVVD investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
On January 31, 2023, a lawsuit was filed on behalf of purchasers of Invivyd, Inc. (NASDAQ: IVVD) common shares between November 29, 2021 and December 14, 2021 over alleged Securities Laws Violations by Invivyd, Inc. The plaintiff alleges that between November 29, 2021 and December 14, 2021, the defendants failed to disclose that the published epitope mapping, structural studies, and sequence analyses which defendants had used to claim ADG20 was effective against the Omicron variant were insufficient, unreliable, and inadequate to make claims of effectiveness of ADG20 against Omicron, that that defendants' claims regarding ADG20's efficacy against Omicron lacked a reasonable factual basis, and that ADG20 was over 300 times less effective against the Omicron variant as compared to its effectiveness against previous variants.
Since its initial public offering ("IPO") shares of Invivyd, Inc. (NASDAQ:IVVD) declined to as low as $1.42 per share on December 30, 2022.
Those who purchased shares of Invivyd, Inc. (NASDAQ:IVVD) between November 29, 2021 and December 14, 2021 should contact the Shareholders Foundation, Inc.
CONTACT:
Shareholders Foundation, Inc. mail@shareholdersfoundation.com
The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. Any referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is only provided as a public service. It is not intended as legal advice and should not be relied upon.
SOURCE: Shareholders Foundation, Inc.
View source version on accesswire.com:
https://www.accesswire.com/741120/Investors-purchased-NASDAQ-IVVD-shares-between-November-29-and-December-14-2021-should-contact-the-Shareholders-Foundation-in-connection-with-the-Lawsuit-against-Invivyd-Inc
IVVD Rankings
#4901 Ranked by Stock Gains
IVVD Stock Data
Industry
Biological Product (except Diagnostic) Manufacturing
Sector
Manufacturing
About IVVD
adagio is developing best-in-class antibodies that can broadly neutralize sars-cov-2, sars-cov-1 and additional potentially emergent coronaviruses. we believe our antibodies will match or exceed the potency and coverage of conventional sars-cov-2 antibody programs and can be used as both therapeutic and durable prophylactic treatments. our candidates are engineered using best-in-industry antibody discovery capabilities and are designed to maximize potency and duration of effect. our portfolio includes multiple, non-competing antibodies with distinct binding targets, enabling a strategy that can avoid viral escape. our lead program is expected to enter the clinic by the end of 2020.
